RDD Blog » drug discovery

R&D Directions Insider

Archive for the ‘ drug discovery ’ Category

Drug repositioning a timely strategy

Monday, December 27th, 2010

With patent expirations looming for several major pharmaceutical companies, the practice of drug repositioning is becoming increasingly important. Drugmakers, also faced with declining R&D productivity levels and an increasingly rigorous regulatory environment, are focused on identifying novel indications and disease targets for existing compounds and securing patent protection before their ...

Posted in Uncategorized, clinical trials, drug discovery | No Comments »

Tool addresses biologic registration limits

Friday, May 7th, 2010

Scientific software company Accelrys Inc. recently unveiled the worldâ€™s first multi-entity, production-ready biologics registration system. Developed from a three-year collaboration withÂ drugmakers including Abbott and Merck & Co., the data tool is designed to helpÂ companies overcome the historically difficult IT challenges associated with registering and defining complex biological materials. Accelrys' database ...

Posted in antibodies, drug discovery | No Comments »

Eyes on screen! Better biological tools sought

Wednesday, November 11th, 2009

If youâ€™re a technology company specializing in high throughput screening and characterization of protein-based drugs, chances are the FDA wants to hear from you. Just call it part of the agencyâ€™s fact-finding mission. With biotech pursuits rapidly becoming a go-to option in mainstream drug development, FDA, like most in the ...

Posted in Uncategorized, drug discovery, vaccines | No Comments »

Roche eyes new talent for Jersey makeover

Wednesday, October 28th, 2009

Roche is looking for a few good cellular biologists. More than a few, to be exact. The pharma giant has launched an ambitious recruitment campaign to add research muscle to its transforming R&D campus in Nutley, N.J., the former site of Rocheâ€™s U.S. commercial operations, since whisked off to South ...

Posted in Uncategorized, drug discovery | No Comments »

Roche deciphers cells with high content screening

Thursday, July 2nd, 2009

While other pharmaceutical companies may be taking a wait-and-see approach, Roche Nutley Research has been moving forward in using digital technology for drug discovery for the past ten years. To help find and validate promising drug candidates, the high content work group at Roche has been deciphering the microscopic language ...

Posted in drug discovery | No Comments »

©2012 UBM Canon